Survey reveals awareness of public reimbursement for bevacizumab in metastatic cervical cancer, indicating treatment gaps.
Figure S4 shows respondents' awareness of the public reimbursement status of bevacizumab in their locations
No takes yet. Share an insight, caveat, or question.
Goh et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: